Post-Marketing Registry, Suicidality Warning Could Be Paradox For Siliq

Labeling for Valeant’s pending plaque psoriasis treatment might warn about the potential for suicide; if that's effective, though, will the company be able to enroll meaningful numbers of patients in its registry that aims for a definitive answer?

Valeant Headquarters

Valeant Pharmaceuticals International Inc. may face a significant challenge in getting a clear answer on whether its plaque psoriasis candidate Siliq (brodalumab) has an increased suicide risk – and efforts to reduce that risk may be part of the problem.

If the product is approved, Valeant is planning to assess Siliq’s potential risk of suicide ideation and behavior with a...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers